Digital health center opening in Denver

Denver is the site of a 300,000-square-foot digital health center, called Catalyst Health-Tech Innovation.

The partnership between a developer and a healthcare entrepreneur hope to make Colorado America’s “digital health capital."

The partnership has acquired a full city block of land in Denver and four companies already plan to be tenants: Corvectra, a Silicon Valley startup working on a needle-free blood sensor; cybersecurity incubator Entrepy; telemedicine startup Telespine, of nearby Boulder; and electronics-maker Premier Manufacturing, which reportedly will create a 3-D lab at Catalyst.

“Catalyst HTI will bring together private enterprise (startups to Fortune 20), government, academic and non­profit organizations with healthcare providers and payers to accelerate innovation and drive real, lasting change for the healthcare industry and our nation,”

The first phase of construction, of a 180,000-square-foot facility, including 10,000 square feet of retail space, will start in about a year, according to Catalyst HTI. It will open by the end of 2017.

Eventually, the complex will grow to 300,000 square feet, and include an events center, a fitness facility, a rooftop deck and a café. The developers said they are designing the space to encourage personal wellness as well as collaboration among tenants.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.